J-code: Drugs administered other than oral method; chemotherapy drugs Drugs administered other than oral method; chemotherapy drugs
1,255 codes
Billing context
J-codes are permanent national codes for drugs and biologicals — most often clinician-administered (buy-and-bill) products paid under Medicare Part B — plus certain immunosuppressive, inhalation (via DME), and oral anticancer/antiemetic drugs. Units are reported in multiples of the dosage in the code descriptor.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| J2505 | Injection, pegfilgrastim, 6 mg | — | Jan 1, 2004 | Ended Dec 31, 2021 |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | $201.241per 0.5 MG | Jan 1, 2022 | Active |
| J2507 | Injection, pegloticase, 1 mg | $4,000.629per 1 MG | Jan 1, 2012 | Active |
| J2508 | Injection, pegunigalsidase alfa-iwxj, 1 mg | $225.998per 1 MG | Jan 1, 2024 | Active |
| J2510 | Injection, penicillin g procaine, aqueous, up to 600,000 units | — | Jan 1, 1982 | Active |
| J2513 | Injection, pentastarch, 10% solution, 100 ml | — | Jan 1, 2006 | Ended Dec 31, 2025 |
| J2515 | Injection, pentobarbital sodium, per 50 mg | — | Jan 1, 1982 | Active |
| J2516 | Injection, pentamidine isethionate, 1 mg | $0.482per 1 MG | Jan 1, 2026 | Active |
| J2540 | Injection, penicillin g potassium, up to 600,000 units | $0.781per 600000 UNITS | Jan 1, 1982 | Active |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | $1.183per 1.125 GM | Jan 1, 2000 | Active |
| J2545 | Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg | $67.047per 300 MG | Jan 1, 1992 | Active |
| J2547 | Injection, peramivir, 1 mg | — | Jan 1, 2016 | Active |
| J2550 | Injection, promethazine hcl, up to 50 mg | $3.241per 50 MG | Jan 1, 1982 | Active |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | $23.369per 120 MG | Jan 1, 1982 | Active |
| J2561 | Injection, phenobarbital sodium (sezaby), 1 mg | — | Jul 1, 2023 | Active |
| J2562 | Injection, plerixafor, 1 mg | $42.943per 1 MG | Jan 1, 2010 | Active |
| J2590 | Injection, oxytocin, up to 10 units | — | Jan 1, 1986 | Active |
| J2596 | Injection, vasopressin (long grove), not therapeutically equivalent to j2598, 1 unit | $1.712per 1 UNIT | Jan 1, 2026 | Active |
| J2597 | Injection, desmopressin acetate, per 1 mcg | $3.475per 1 MCG | Jan 1, 1996 | Active |
| J2598 | Injection, vasopressin, 1 unit | $0.566per 1 UNIT | Jul 1, 2023 | Active |
| J2599 | Injection, vasopressin (american regent), not therapeutically equivalent to j2598, 1 unit | $0.574per 1 UNIT | Jul 1, 2023 | Active |
| J2601 | Injection, vasopressin (baxter), 1 unit | $2.328per 1 UNIT | Oct 1, 2024 | Active |
| J2650 | Injection, prednisolone acetate, up to 1 ml | — | Jan 1, 1982 | Active |
| J2670 | Injection, tolazoline hcl, up to 25 mg | — | Jan 1, 1986 | Active |
| J2675 | Injection, progesterone, per 50 mg | $0.623per 50 MG | Jan 1, 1986 | Active |
| J2679 | Injection, fluphenazine hcl, 1.25 mg | $7.269per 1.25 MG | Jan 1, 2024 | Active |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | $6.174per 25 MG | Jan 1, 1982 | Active |
| J2690 | Injection, procainamide hcl, up to 1 gm | $394.868per 1 GM | Jan 1, 1982 | Active |
| J2700 | Injection, oxacillin sodium, up to 250 mg | $0.768per 250 MG | Jan 1, 1982 | Active |
| J2704 | Injection, propofol, 10 mg | $0.093per 10 MG | Jan 1, 2015 | Active |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | — | Jan 1, 1982 | Active |
| J2711 | Injection, neostigmine methylsulfate 0.1 mg and glycopyrrolate 0.02 mg | — | Jan 1, 2026 | Active |
| J2720 | Injection, protamine sulfate, per 10 mg | $1.785per 10 MG | Jan 1, 1982 | Active |
| J2724 | Injection, protein c concentrate, intravenous, human, 10 iu | $15.034per 10 UNITS | Jan 1, 2008 | Active |
| J2725 | Injection, protirelin, per 250 mcg | — | Jan 1, 1995 | Active |
| J2730 | Injection, pralidoxime chloride, up to 1 gm | — | Jan 1, 1986 | Active |
| J2760 | Injection, phentolamine mesylate, up to 5 mg | $296.849per 5 MG | Jan 1, 1982 | Active |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | $0.891per 10 MG | Jan 1, 1982 | Active |
| J2770 | Injection, quinupristin/dalfopristin, 500 mg (150/350) | — | Jan 1, 2001 | Active |
| J2777 | Injection, faricimab-svoa, 0.1 mg | $31.322per 0.1 MG | Oct 1, 2022 | Active |
| J2778 | Injection, ranibizumab, 0.1 mg | $26.384per 0.1 mg | Jan 1, 2008 | Active |
| J2779 | Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg | $73.542per 0.1 MG | Jul 1, 2022 | Active |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | — | Jan 1, 2000 | Ended Jun 30, 2024 |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | $135.267per 1 MG | Oct 1, 2023 | Active |
| J2782 | Injection, avacincaptad pegol, 0.1 mg | $100.563per 0.1 MG | Apr 1, 2024 | Active |
| J2783 | Injection, rasburicase, 0.5 mg | $386.628per 0.5 MG | Jan 1, 2004 | Active |
| J2785 | Injection, regadenoson, 0.1 mg | $2.507per 0.1 MG | Jan 1, 2009 | Active |
| J2786 | Injection, reslizumab, 1 mg | $11.907per 1 MG | Jan 1, 2017 | Active |
| J2787 | Riboflavin 5'-phosphate, ophthalmic solution (photrexa viscous/photrexa), up to 3 ml | — | Jan 1, 2019 | Active |
| J2788 | Injection, rho d immune globulin, human, minidose, 50 micrograms (250 i.u.) | $27.653per 50 MCG (250 IU) | Jan 1, 2003 | Active |
| J2789 | Riboflavin 5'-phosphate, ophthalmic solution (epioxahd/epioxa), up to 2 ml | $41,359.618per UP TO 2 ML | Jul 1, 2026 | Active |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | $82.081per 300 MCG (1500 IU) | Jan 1, 1986 | Active |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | $4.837per 100 IU | Jan 1, 2008 | Active |
| J2792 | Injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu | $35.395per 100 IU | Jan 1, 1999 | Active |
| J2793 | Injection, rilonacept, 1 mg | — | Jan 1, 2010 | Active |
| J2794 | Injection, risperidone (risperdal consta), 0.5 mg | $10.662per 0.5 MG | Jan 1, 2005 | Active |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | $0.040per 1 MG | Jan 1, 2001 | Active |
| J2796 | Injection, romiplostim, 10 micrograms | — | Jan 1, 2010 | Ended Dec 31, 2024 |
| J2797 | Injection, rolapitant, 0.5 mg | — | Jan 1, 2019 | Active |
| J2798 | Injection, risperidone, (perseris), 0.5 mg | $12.191per 0.5 mg | Oct 1, 2019 | Active |
| J2799 | Injection, risperidone (uzedy), 1 mg | $26.227per 1 MG | Jan 1, 2024 | Active |
| J2800 | Injection, methocarbamol, up to 10 ml | $3.839per 10 ML | Jan 1, 1982 | Active |
| J2801 | Injection, risperidone (rykindo), 0.5 mg | — | Apr 1, 2024 | Active |
| J2802 | Injection, romiplostim, 1 microgram | $11.713per 1 MCG | Jan 1, 2025 | Active |
| J2804 | Injection, rifampin, 1 mg | $0.165per 1 MG | Apr 1, 2025 | Active |
| J2805 | Injection, sincalide, 5 micrograms | $145.638per 5 MCG | Jan 1, 2006 | Active |
| J2806 | Injection, sincalide (maia), not therapeutically equivalent to j2805, 5 micrograms | — | Jul 1, 2023 | Ended Dec 31, 2024 |
| J2810 | Injection, theophylline, per 40 mg | — | Jan 1, 1982 | Active |
| J2820 | Injection, sargramostim (gm-csf), 50 mcg | $62.470per 50 MCG | Jan 1, 1982 | Active |
| J2840 | Injection, sebelipase alfa, 1 mg | — | Jan 1, 2017 | Active |
| J2850 | Injection, secretin, synthetic, human, 1 microgram | — | Jan 1, 2006 | Active |
| J2860 | Injection, siltuximab, 10 mg | $178.427per 10 MG | Jan 1, 2016 | Active |
| J2865 | Injection, sulfamethoxazole 5 mg and trimethoprim 1 mg | $0.034per 5MG-1MG | Apr 1, 2025 | Active |
| J2910 | Injection, aurothioglucose, up to 50 mg | — | Jan 1, 1982 | Ended Dec 31, 2025 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | $1.956per 12.5 MG | Jan 1, 2003 | Active |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | $0.255per 5 MG | Apr 1, 2024 | Active |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | — | Jan 1, 1982 | Ended Mar 31, 2024 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | — | Jan 1, 1984 | Ended Mar 31, 2024 |
| J2940 | Injection, somatrem, 1 mg | — | Jan 1, 2002 | Ended Dec 31, 2025 |
| J2941 | Injection, somatropin, 1 mg | — | Jan 1, 2002 | Active |
| J2950 | Injection, promazine hcl, up to 25 mg | — | Jan 1, 1982 | Active |
| J2993 | Injection, reteplase, 18.1 mg | — | Jan 1, 2001 | Active |
| J2995 | Injection, streptokinase, per 250,000 iu | — | Jan 1, 1986 | Ended Dec 31, 2025 |
| J2997 | Injection, alteplase recombinant, 1 mg | $98.416per 1 MG | Jan 1, 2001 | Active |
| J2998 | Injection, plasminogen, human-tvmh, 1 mg | — | Jul 1, 2022 | Active |
| J3000 | Injection, streptomycin, up to 1 gm | $16.407per 1 GM | Jan 1, 1982 | Active |
| J3010 | Injection, fentanyl citrate, 0.1 mg | $1.362per 0.1 MG | Jan 1, 1982 | Active |
| J3030 | Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | — | Jan 1, 1986 | Active |
| J3031 | Injection, fremanezumab-vfrm, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered) | — | Oct 1, 2019 | Active |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | $21.243per 1 MG | Oct 1, 2020 | Active |
| J3055 | Injection, talquetamab-tgvs, 0.25 mg | $77.473per 0.25 MG | Apr 1, 2024 | Active |
| J3060 | Injection, taliglucerase alfa, 10 units | $42.473per 10 UNITS | Jan 1, 2014 | Active |
| J3070 | Injection, pentazocine, 30 mg | — | Jan 1, 1982 | Active |
| J3090 | Injection, tedizolid phosphate, 1 mg | $2.062per 1 MG | Jan 1, 2016 | Active |
| J3095 | Injection, telavancin, 10 mg | $8.149per 10 MG | Jan 1, 2011 | Active |
| J3101 | Injection, tenecteplase, 1 mg | $230.742per 1 MG | Jan 1, 2009 | Active |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | $1.000per 1 MG | Jan 1, 1987 | Active |
| J3110 | Injection, teriparatide, 10 mcg | — | Jan 1, 2005 | Active |
| J3111 | Injection, romosozumab-aqqg, 1 mg | $12.792per 1 MG | Oct 1, 2019 | Active |
| J3120 | Injection, testosterone enanthate, up to 100 mg | — | Jan 1, 1982 | Ended Dec 31, 2014 |